Get the Stockscreener App
43.65
1.32%
0.57
After Hours:
43.65
Qiagen Nv stock is traded at $43.65, with a volume of 1.25M.
It is up +1.32% in the last 24 hours and up +0.18% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$43.08
Open:
$43.56
24h Volume:
1.25M
Relative Volume:
1.14
Market Cap:
$9.71B
Revenue:
$1.94B
Net Income/Loss:
$72.70M
P/E Ratio:
30.10
EPS:
1.45
Net Cash Flow:
$405.21M
1W Performance:
+4.43%
1M Performance:
+0.18%
6M Performance:
+1.56%
1Y Performance:
+7.98%
1-Day Range:
$43.45
$43.85
1-Week Range:
$41.58
$43.85
52-Week Range:
$38.68
$47.44
Qiagen Nv Stock (QGEN) Company Profile
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel - Yahoo Finance
Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics - GlobeNewswire
Qiagen Receives FDA Clearance Of Qiastat-Dx Meningitis/Encephalitis Panel To Support Emergency Diagnostics - XM
Forsta AP Fonden Sells 18,586 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen (QGEN) Set to Announce Earnings on Wednesday - MarketBeat
Raymond James & Associates Trims Position in Qiagen (NYSE:QGEN) - MarketBeat
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire Inc.
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment - GlobeNewswire
Qiagen Receives FDA Clearance For Qiastat-Dx Mini Panel - XM
Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note - MSN
Insiders At Qiagen Sold US$7.0m In Stock, Alluding To Potential Weakness - Simply Wall St
Qiagen (NYSE:QGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Verogen Hit With Genetic-Privacy Suit Over Acquisition by Qiagen - Bloomberg Law
HSBC Downgrades Qiagen N.V. (QGEN) - MSN
Cancer Biomarkers Industry Analysis and Market Opportunities, Forecast to 2029A Forecasted $42 Billion Landscape, Dominated by Roche, Thermo Fisher Scientific, QIAGEN, Illumina, and Bio-Rad Labs - Yahoo Finance
Vontobel Holding Ltd. Sells 29,019 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen (NYSE:QGEN) Upgraded at Hsbc Global Res - MarketBeat
Qiagen N.V. (NYSE:QGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Qiagen (NYSE:QGEN) Rating Lowered to Hold at HSBC - MarketBeat
HSBC cautious on Qiagen stock, highlights pricing and revenue risks - Investing.com
HSBC cautious on Qiagen stock, highlights pricing and revenue risks By Investing.com - Investing.com Canada
HSBC Downgrades Qiagen NV (QGEN) to Hold - StreetInsider.com
QIAGEN NV : DZ Bank reiterates its Buy rating - Marketscreener.com
CE Mark Granted To Qiagen's QIAstat-Dx Syndromic Testing Instruments, Assays - MPO-mag
Mycoplasma Plate Antigen Market 2024-2031- Charles River, Prospec-Tany Technogene Ltd, Abnova Corporation, Qiagen N.V., – IndiaPolitics.com - IndiaPolitics.com
Cubist Systematic Strategies LLC Decreases Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Is in Huge Demand:Qiagen NV, GE Healthca – IndiaPolitics.com - IndiaPolitics.com
Exchange Traded Concepts LLC Sells 62,505 Shares of Qiagen (NYSE:QGEN) - MarketBeat
QIAGEN's TB Testing Business Gets New Exposure at Global Summit - Yahoo Finance
Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S - Simply Wall St
QIAGEN expands automated liquid biopsy portfolio to enhance - GlobeNewswire
QIAGEN Expands Automated Liquid Biopsy Portfolio To Enhance Oncology, Prenatal Care And Organ Transplant Applications - XM
QIAGEN Expands Automated Liquid Biopsy Portfolio to Enhance Oncology, Prenatal Care and Organ Transplant Applications - Marketscreener.com
QIAGEN N.V. to release results for Q3 2024 and hold webcast - The Manila Times
QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications - StockTitan
Handelsbanken Fonder AB Purchases 19,900 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen N : Digital Insights Expands Biopharma Collaboration with Neo4j to advance Biomedical Data Analysis - Marketscreener.com
Reasons to Retain QIAGEN Stock in Your Portfolio for Now - MSN
Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer - The Manila Times
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology - SelectScience
QGENQIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology - br.ADVFN.com
Oxidative Stress Analysis Market Dynamics Analysis – Abcam, Enzo Biochem, Merck, Qiagen NV - Cauverynews
Qiagen launches QIAcuityDx digital PCR system for clinical testing in oncology - BSA bureau
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.73%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):